-
Je něco špatně v tomto záznamu ?
Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance
Z. Heger, MA. Rodrigo, S. Krizkova, B. Ruttkay-Nedecky, M. Zalewska, EM. Del Pozo, A. Pelfrene, B. Pourrut, M. Stiborova, T. Eckschlager, G. Emri, R. Kizek, V. Adam,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- antracykliny aplikace a dávkování škodlivé účinky MeSH
- chemorezistence MeSH
- kardiomyopatie etiologie prevence a kontrola MeSH
- kardiotonika farmakologie MeSH
- lidé MeSH
- metalothionein metabolismus farmakologie MeSH
- nádory farmakoterapie patologie MeSH
- oxidační stres účinky léků MeSH
- protinádorová antibiotika aplikace a dávkování škodlivé účinky MeSH
- scavengery volných radikálů farmakologie MeSH
- srdeční selhání chemicky indukované prevence a kontrola MeSH
- volné radikály metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Cardiotoxicity is a serious complication of anticancer therapy by anthracycline antibiotics. Except for intercalation into DNA/RNA structure, inhibition of DNA-topoisomerase and histone eviction from chromatin, the main mechanism of their action is iron-mediated formation of various forms of free radicals, which leads to irreversible damage to cancer cells. The most serious adverse effect of anthracyclines is, thus, cardiomyopathy leading to congestive heart failure, which is caused by the same mechanisms. Here, we briefly summarize the basic types of free radicals formed by anthracyclines and the main processes how to scavenge them. From these, the main attention is paid to metallothioneins. These low-molecular cysteine-rich proteins are introduced and their functions and properties are reviewed. Further, their role in detoxification of metals and drugs is discussed. Based on these beneficial roles, their use as a new therapeutic agent against oxidative stress and for cardioprotection is critically evaluated with respect to their ability to increase chemoresistance against some types of commonly used cytostatics.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031896
- 003
- CZ-PrNML
- 005
- 20171122122734.0
- 007
- ta
- 008
- 171025s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1389450116666151001113304 $2 doi
- 035 __
- $a (PubMed)26424389
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Heger, Zbynek
- 245 10
- $a Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance / $c Z. Heger, MA. Rodrigo, S. Krizkova, B. Ruttkay-Nedecky, M. Zalewska, EM. Del Pozo, A. Pelfrene, B. Pourrut, M. Stiborova, T. Eckschlager, G. Emri, R. Kizek, V. Adam,
- 520 9_
- $a Cardiotoxicity is a serious complication of anticancer therapy by anthracycline antibiotics. Except for intercalation into DNA/RNA structure, inhibition of DNA-topoisomerase and histone eviction from chromatin, the main mechanism of their action is iron-mediated formation of various forms of free radicals, which leads to irreversible damage to cancer cells. The most serious adverse effect of anthracyclines is, thus, cardiomyopathy leading to congestive heart failure, which is caused by the same mechanisms. Here, we briefly summarize the basic types of free radicals formed by anthracyclines and the main processes how to scavenge them. From these, the main attention is paid to metallothioneins. These low-molecular cysteine-rich proteins are introduced and their functions and properties are reviewed. Further, their role in detoxification of metals and drugs is discussed. Based on these beneficial roles, their use as a new therapeutic agent against oxidative stress and for cardioprotection is critically evaluated with respect to their ability to increase chemoresistance against some types of commonly used cytostatics.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antracykliny $x aplikace a dávkování $x škodlivé účinky $7 D018943
- 650 _2
- $a protinádorová antibiotika $x aplikace a dávkování $x škodlivé účinky $7 D000903
- 650 _2
- $a kardiomyopatie $x etiologie $x prevence a kontrola $7 D009202
- 650 _2
- $a kardiotonika $x farmakologie $7 D002316
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a scavengery volných radikálů $x farmakologie $7 D016166
- 650 _2
- $a volné radikály $x metabolismus $7 D005609
- 650 _2
- $a srdeční selhání $x chemicky indukované $x prevence a kontrola $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metalothionein $x metabolismus $x farmakologie $7 D008668
- 650 _2
- $a nádory $x farmakoterapie $x patologie $7 D009369
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Rodrigo, Miguel Angel Merlos
- 700 1_
- $a Krizkova, Sona
- 700 1_
- $a Ruttkay-Nedecky, Branislav
- 700 1_
- $a Zalewska, Marta
- 700 1_
- $a Del Pozo, Elena Maria Planells
- 700 1_
- $a Pelfrene, Aurelie
- 700 1_
- $a Pourrut, Bertrand
- 700 1_
- $a Stiborova, Marie
- 700 1_
- $a Eckschlager, Tomas
- 700 1_
- $a Emri, Gabriella
- 700 1_
- $a Kizek, Rene
- 700 1_
- $a Adam, Vojtěch $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic. vojtech.adam@mendelu.cz. $7 xx0064599
- 773 0_
- $w MED00007902 $t Current drug targets $x 1873-5592 $g Roč. 17, č. 12 (2016), s. 1438-51
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26424389 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171122122854 $b ABA008
- 999 __
- $a ok $b bmc $g 1255489 $s 992923
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 17 $c 12 $d 1438-51 $i 1873-5592 $m Current drug targets $n Curr Drug Targets $x MED00007902
- LZP __
- $a Pubmed-20171025